CNS Pharmaceuticals Inc. Common Stock (NASDAQ:CNSP)

Real-time price: | Most recent change:0.00%

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is based in Houston, United States....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 4 July 2026

Blog+More

AYA Analytica podcast provides fresh insights into the latest stock market issues, economic trends, and investment portfolio strategies.

Daphne Basel

2019-05-30 16:44:00 Thursday ET

AYA Analytica podcast provides fresh insights into the latest stock market issues, economic trends, and investment portfolio strategies.

AYA Analytica finbuzz podcast channel on YouTube May 2019 In this podcast, we discuss several topical issues as of May 2019: (1) Our proprietary alp

+See More

Ray Fair applies his macroeconometric model to study the central features of the U.S. macroeconomy such as price stability and full employment in the dual mandate.

Charlene Vos

2023-07-14 10:32:00 Friday ET

Ray Fair applies his macroeconometric model to study the central features of the U.S. macroeconomy such as price stability and full employment in the dual mandate.

Ray Fair applies his macroeconometric model to study the central features of the U.S. macroeconomy such as price stability and full employment in the dual m

+See More

State, society, and the narrow corridor to liberty

Joseph Corr

2023-09-28 08:26:00 Thursday ET

State, society, and the narrow corridor to liberty

Daron Acemoglu and James Robinson show a constant economic tussle between society and the state in the hot pursuit of liberty. Daron Acemoglu and James R

+See More

The Trump administration blames China for egregious currency misalignment.

Olivia London

2018-10-17 12:33:00 Wednesday ET

The Trump administration blames China for egregious currency misalignment.

The Trump administration blames China for egregious currency misalignment, but this criticism cannot confirm *currency manipulation* on the part of the Chin

+See More

President Donald Trump releases his plan to slash income taxes for U.S. citizens and corporations.

Jacob Miramar

2017-09-03 10:44:00 Sunday ET

President Donald Trump releases his plan to slash income taxes for U.S. citizens and corporations.

President Donald Trump has released his plan to slash income taxes for U.S. citizens and corporations. The corporate income tax rate will decline from 35% t

+See More

Corporate diversification theory and evidence

James Campbell

2022-04-05 17:39:00 Tuesday ET

Corporate diversification theory and evidence

Corporate diversification theory and evidence A recent strand of corporate diversification literature spans at least three generations. The first generat

+See More